

Date: 24/05/2022

To, Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort Mumbai –400001

SCRIP CODE: 542721

Sub: Submission of Annual Secretarial Compliance Report for the year ended 31st March, 2022

Dear Sir / Madam,

Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements). Regulations, 2015 as amended read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 8thFebruary 2019, please find enclosed copy of Annual Secretarial Compliance Report dated 24th May, 2022 for the financial year 2021-22 issued by M/s Paliwal & Co., Practicing Company Secretaries.

This is for your information and records please.

Thanking you, For ANAND RAYONS LIMITED



busha

Varsha Maheshwari (Company Secretary & Compliance Officer)

Encl: As above

ANAND RAYONS LIMITED

Registered Office: 305-306, Jay Sagar Complex, B/h. Sub Jail, Khatodara, Surat -395 002. Ph : +91-261-4005667 Web Site: www.anandrayons.com, Email: -info@anandrayons.com, anandrayonsltd@gmail.com, CIN: L51909GJ2018PLC104200



Office: 401, Haash Complex, Nagri Hospital-Law Garden Road, Nr. Ellise Bridge Police Line, Ahmedabad-380006 Email Ids. welcome2pcs@gmail.com, alpesh.pcs@gmail.com,Ph. 079 - 48980181, Contact Nos. 8000133307

Annual Secretarial Compliance Report of Anand Rayons Limited for the year ended 31/03/2022

I have examined:

- (a) All the documents and records made available to us and explanation provided by M/s. Anand Rayons Limited (CIN: L51909GJ2018PLC104200) (hereinafter called "the listed entity"),
- (b) The filings/ submissions made by the listed entity to the stock exchanges,
- (c) Website of the listed entity,
- (d) Any other document/filing, as may be relevant, which has been relied upon to make this certification,

For the year ended **31st March, 2022** ("Review Period") in respect of compliance with the provisions of:

- (a) The Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued thereunder; and
- (b) the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India ("SEBI");

The specific Regulations, whose provisions and the circulars/ guidelines issued thereunder, have been examined, include:-

(a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;



Office: 401, Haash Complex, Nagri Hospital-Law Garden Road, Nr. Ellise Bridge Police Line, Ahmedabad-380006 Email Ids. welcome2pcs@gmail.com, alpesh.pcs@gmail.com,Ph. 079 - 48980181, Contact Nos. 8000133307

- (b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
- (c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- (d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; (Not applicable to the Company during the Reporting Period);
- (e) Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2021; (Not applicable to the Company during the Reporting Period);
- (f) Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; (Not applicable to the Company during the Reporting Period);
- (g) Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; (Not applicable to the Company during the Reporting Period);
- (h) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- (i) The Company has complied with clause 6(A) and 6(B) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations") of the SEBI Circular no. CIR/CFD/CMD1/27/2019 (ated February 08, 2019.



Office: 401, Haash Complex, Nagri Hospital-Law Garden Road, Nr. Ellise Bridge Police Line, Ahmedabad-380006 Email Ids. welcome2pcs@gmail.com, alpesh.pcs@gmail.com,Ph. 079 – 48980181, Contact Nos. 8000133307

And based on the above examination and considering the relaxations granted by the Ministry of Corporate Affairs and Securities and Exchange Board of India, I hereby report that, during the Review Period:

(a) The listed entity has complied with the provisions of the above Regulations and circulars/ guidelines issued thereunder, except in respect of matters specified below:-

Sr.	Compliance Requirement	Deviations	Observations/remarksofthePracticingCompanySecretary	
No	(Regulations/circulars/ guidelines including specific clause)			
		NA		

- (b) The listed entity has maintained proper records under the provisions of the above Regulations and circulars/ guidelines issued thereunder in so far as it appears from my examination of those records.
- (c) The following are the details of actions taken against the listed entity/its promoters/directors/material subsidiaries either by SEBI or by Stock Exchanges (including under the Standard Operating Procedures issued by SEBI through various circulars) under the aforesaid Acts/ Regulations and circulars/ guidelines issued thereunder:

Sr.	Action	Details of	Details of action	Observations/ remarks of
No	taken by	violation	taken e.g. fines, warning letter, debarment, etc.	the Practicing Company Secretary, if any
			NA	PALINAL



Paliwal & Co. (Formerly Known as Alpesh Dhandhlya & Associates) Company Secretaries

Office: 401, Haash Complex, Nagri Hospital-Law Garden Road, Nr. Ellise Bridge Police Line, Ahmedabad-380006 Email Ids. welcome2pcs@gmail.com, alpesh.pcs@gmail.com,Ph. 079 – 48980181, Contact Nos. 8000133307

(d) The listed entity has taken the following actions to comply with the observations made in previous reports:

a second s		Actions taken by the listed entity, if any	the
reports	secretarial complianc e report for the year ended		Company Secretary on the actions taken by the listed entity
	NA		

Date: 24/05/2022 Place: Ahmedabad For, Paliwal & Co. (Formerly known as Alpesh Dhandhlya & Associates) Company Secretaries

MEN No.: 32500 COP No.: 12119 UCN: I2013GJ1046200 Peer Review Registration Number: 1686/2022 UDIN: A032500D000376371

MALAL